Migraine affects approximately 1 billion people worldwide and 39 million Americans, making it one of the most prevalent neurological conditions on the planet. It is the sixth-leading cause of disability globally, according to the Global Burden of Disease study. Despite the availability of triptans, CGRP inhibitors, and other pharmaceutical treatments, a substantial proportion of migraine sufferers — estimated at 40–50% — are unsatisfied with their current treatment or experience inadequate relief.
Into this gap has stepped cannabis. Surveys consistently show that migraine is among the top five conditions for which patients seek medical cannabis. But does the clinical evidence support this use? The answer is more encouraging than many physicians assume, though it comes with the caveats that characterize nearly all cannabis research.
The Historical Context
Cannabis was one of the most widely prescribed treatments for migraine in Western medicine from the mid-1800s through the early 1900s. Sir William Osler, often called the father of modern medicine, wrote in his 1892 textbook The Principles and Practice of Medicine that cannabis indica was probably the most satisfactory remedy for migraine headache. Cannabis appeared in the United States Pharmacopeia as a migraine treatment until 1942, when it was removed following the Marihuana Tax Act.
This historical use is not evidence by modern standards, but it does indicate that the relationship between cannabis and headache relief was recognized by experienced clinicians for over a century before prohibition.
The Endocannabinoid Deficiency Hypothesis
One of the most influential theoretical frameworks for understanding cannabis and migraine is the Clinical Endocannabinoid Deficiency (CED) hypothesis, proposed by neurologist Ethan Russo in 2004 and updated in 2016 in Cannabis and Cannabinoid Research.
The CED hypothesis proposes that migraine, fibromyalgia, irritable bowel syndrome, and certain other treatment-resistant conditions share a common underlying pathophysiology: a deficiency in endocannabinoid tone — either reduced endocannabinoid production, increased endocannabinoid degradation, or reduced receptor expression.
Supporting evidence for CED in migraine includes:
Reduced anandamide levels. A 2007 study by Sarchielli et al. published in Neuropsychopharmacology measured cerebrospinal fluid (CSF) levels of anandamide in chronic migraine patients and found significantly reduced levels compared to controls. Anandamide levels were inversely correlated with headache severity.
Altered endocannabinoid metabolism. A 2006 study by Cupini et al. found that platelets from female migraine patients showed increased activity of FAAH (fatty acid amide hydrolase), the enzyme that breaks down anandamide. This would result in faster degradation of endocannabinoids, producing a functional deficiency even if production were normal.
CGRP-endocannabinoid interaction. Calcitonin gene-related peptide (CGRP) is now recognized as a central mediator of migraine pathophysiology — the new anti-CGRP drugs (erenumab, fremanezumab, galcanezumab) represent the first migraine-specific preventive class in decades. Endocannabinoids modulate CGRP release in the trigeminal system. Anandamide has been shown to inhibit dural CGRP release in animal models, suggesting a direct mechanism by which endocannabinoid deficiency could promote migraine.
The Clinical Evidence
Retrospective and Observational Studies
Rhyne et al. (2016), Pharmacotherapy. One of the first published clinical studies of cannabis for migraine. A retrospective chart review of 121 adults with migraine who were recommended medical cannabis by a Colorado clinic. Migraine frequency decreased from an average of 10.4 headaches per month to 4.6 — a 55.7% reduction. Of the 121 patients, 103 (85.1%) reported decreased migraine frequency. Nineteen patients (15.3%) reported that inhaled cannabis aborted acute migraine attacks.
Aviram and Samuelly (2017), European Journal of Neurology. A prospective study of 145 migraine patients using medical cannabis in Israel. After six months, mean monthly migraine frequency dropped from 8.7 to 5.9 episodes (32.2% reduction). Acute severity scores also decreased significantly. Headache duration showed a non-significant trend toward reduction.
Baron et al. (2018), The Journal of Headache and Pain. A survey of 2,032 medical cannabis patients, 527 of whom used cannabis specifically for headache or migraine. Among migraine patients, 49.6% reported a reduction in headache frequency, and 43.3% reported reduced severity. Those using both THC and CBD reported better outcomes than those using CBD alone.
Controlled Trials
Nicolodi et al. (2017), Congress of the European Academy of Neurology. This Italian study is among the most frequently cited. In a Phase I dose-finding component, 48 chronic migraine patients received escalating doses of a THC-CBD combination (19:9 ratio). At 200 mg daily, participants experienced a 55% reduction in pain severity for acute migraine attacks. In a Phase II component, 79 chronic migraine patients were randomized to either the THC-CBD combination (200 mg/day) or amitriptyline (25 mg/day) for three months. Both treatments reduced migraine frequency by approximately 40%. The THC-CBD combination was 43.5% more effective at reducing acute attack pain intensity. However, this study was presented as a conference abstract and the full methodology has been scrutinized for limited peer-review detail.
Stith et al. (2020), Journal of Integrative Medicine. Analysis of real-time data from the Releaf app, which tracks patient-reported cannabis use for symptom relief. Among 12,293 sessions of cannabis use for headache, users reported an average 47.3% reduction in headache severity. Among sessions for migraine specifically, the average reduction was 49.6%. Inhaled cannabis produced faster relief (within 30 minutes) than edibles.
Summary of Clinical Findings
| Study | Design | Patients | Primary Finding |
|---|---|---|---|
| Rhyne 2016 | Retrospective | 121 | 55.7% reduction in monthly frequency |
| Aviram 2017 | Prospective | 145 | 32.2% reduction in monthly frequency |
| Baron 2018 | Survey | 527 | 49.6% reported frequency reduction |
| Nicolodi 2017 | Phase II RCT | 79 | Similar to amitriptyline; better for acute pain |
| Stith 2020 | App-tracked data | 12,293 sessions | 49.6% average severity reduction per session |
Mechanisms of Action
Cannabis likely affects migraine through multiple pharmacological mechanisms:
Serotonin system modulation. THC and CBD interact with serotonin receptors, particularly 5-HT1A. Serotonin dysregulation is central to migraine pathophysiology — triptans work primarily by activating 5-HT1B/1D receptors. CBD is a partial agonist at 5-HT1A, which may contribute to anti-migraine effects through a mechanism somewhat analogous to triptans.
Anti-inflammatory effects. Neurogenic inflammation in the dural meninges is a key component of migraine. Both THC and CBD have demonstrated anti-inflammatory properties in neural tissue. CBD inhibits adenosine reuptake, increasing extracellular adenosine levels, which has anti-inflammatory and potentially anti-nociceptive effects.
CGRP inhibition. As noted above, endocannabinoids modulate CGRP release in the trigeminal system. This mechanism is particularly relevant given the success of pharmaceutical CGRP inhibitors for migraine.
Central and peripheral analgesia. CB1 receptor activation in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) — key pain-modulating brain regions — produces descending inhibition of pain signals, including those from the trigeminal nucleus caudalis, which processes head and face pain.
Vasomotor effects. The relationship between cannabis and blood vessel tone is complex, but cannabinoids can modulate cerebral blood flow. Some migraine auras are associated with cortical spreading depression and vascular changes. The role of cannabinoids in these processes is under investigation.
Acute vs. Preventive Use
An important distinction in migraine treatment is between acute treatment (taken during an attack to stop it) and preventive treatment (taken regularly to reduce frequency and severity of future attacks).
Acute use. Inhaled cannabis appears to be more effective for acute migraine treatment than oral forms, likely due to the rapid onset of inhaled THC (5–15 minutes vs. 60–120 minutes for edibles). The Stith (2020) Releaf app data showed that 94% of headache sessions resulted in some symptom reduction, with a mean time to relief of approximately 30 minutes for inhaled flower. However, no controlled trial has directly compared inhaled cannabis to triptans or other standard acute treatments.
Preventive use. The observational data showing sustained reductions in monthly migraine frequency over 3–6 months suggests a preventive effect, but the mechanism is unclear. It could involve tonic elevation of endocannabinoid signaling, anti-inflammatory effects, or changes in central sensitization over time.
Risks and Considerations
Medication overuse headache (MOH). This is the most important concern. MOH occurs when the frequent use of any acute headache treatment — triptans, NSAIDs, opioids, or potentially cannabis — paradoxically increases headache frequency. A 2018 review in Cephalalgia noted that cannabis may carry MOH risk, particularly with daily or near-daily acute use. Patients using cannabis for migraine should be aware of this risk and should avoid daily acute use if possible.
Rebound headache on cessation. Headache is a recognized symptom of cannabis withdrawal. For migraine patients who use cannabis regularly and then stop, the withdrawal headache can be difficult to distinguish from a worsening of their underlying migraine condition.
Cardiovascular effects. THC increases heart rate acutely and may affect blood pressure. For migraine patients with cardiovascular comorbidities, this requires consideration — particularly since triptans are also contraindicated in certain cardiovascular conditions.
Dosing inconsistency. Unlike pharmaceutical treatments, cannabis products (outside of prescription synthetic cannabinoids) vary widely in potency, cannabinoid ratios, and terpene profiles. This makes consistent dosing challenging, which is a practical problem for a condition that benefits from standardized, reproducible treatment.
Practical Guidance for Migraine Patients
Based on the available evidence, several practical conclusions can be drawn:
For acute treatment: Inhaled cannabis (vaporized flower or concentrates) provides the fastest onset. Products with a balanced THC:CBD ratio or a moderate THC content (10–20%) appear well-suited based on the available data. Start with a low dose (one to two inhalations) and wait 15 minutes before taking more.
For preventive use: Daily low-dose CBD (25–50 mg) is being explored as a migraine preventive based on its anti-inflammatory and serotonergic properties. No definitive preventive dosing protocol exists, but the Nicolodi study used 200 mg/day of a THC-CBD combination as a preventive.
Tracking and documentation: Migraine patients should track headache frequency, severity, duration, and cannabis use in a headache diary. This allows for objective assessment of whether cannabis is reducing migraine burden over time.
Discuss with your neurologist. Headache medicine is a rapidly evolving specialty. Many neurologists are now open to discussing cannabis as part of a comprehensive migraine treatment plan, particularly for patients who have not responded to conventional therapies.
Where the Research Stands
The evidence base for cannabis and migraine is stronger than for many conditions for which cannabis is commonly used. The observational data is consistently positive, showing frequency reductions of 30–55% across multiple studies. The limited controlled data is promising but insufficient for definitive conclusions.
What the field needs — and what several research groups are actively pursuing — is a series of well-designed, adequately powered, randomized controlled trials comparing specific cannabinoid formulations to established migraine treatments (triptans, CGRP inhibitors) using standardized migraine outcome measures. Until those trials are completed, the evidence supports cannabis as a reasonable option for migraine patients, particularly those who have not responded adequately to conventional treatments, with the caveat that optimal dosing, formulation, and treatment regimens remain to be defined.
For the millions of migraine sufferers who have already tried cannabis and found relief, the existing research validates their experience. For their physicians, the evidence warrants engagement rather than dismissal. And for the research community, the endocannabinoid-migraine connection represents one of the most promising and biologically plausible areas in cannabinoid medicine.